GeneThera, Inc. GTHA ? Test Now Available for Mad Cow Disease.
Tuesday December 30, 9:00 am ET
WHEAT RIDGE, CO--(MARKET WIRE)--Dec 30, 2003 -- GeneThera, Inc. (OTC BB: GTHA) announced today that they have the capability to test for Mad Cow Disease in live animals. GeneThera's test, originally designed for the detection of Mad Cow Disease in live animals has been successfully applied to Chronic Wasting Disease due to its presence in the Western United States. Since the two diseases are nearly identical, belonging to the Transmissible Spongiform Encephalopathy (TSE) family, the test works equally well with both diseases. This test should become the standard for all cattle industry testing of Mad Cow Disease, as no other blood test is available that works on live animals.
The test uses proprietary technology for detection and quantification of TSE. This will enable ranchers to test their animals on an ongoing basis without having to slaughter them. The test is also very quick, with results usually available within 24-48 hours.
Dr. Antonio Milici, CEO of GeneThera, Inc., stated, "We are extremely excited to be able to offer the industry a live blood test relatively non-invasive for Mad Cow Disease." He went on to add, "The recent news that Mad Cow Disease was found here in the United States will afford us the opportunity to start testing animals at our laboratory in Colorado and look forward to working with the USDA to provide any assistance in solving the mad cow disease problem."
About GeneThera:
GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA?, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne's Disease, diseases affecting cattle worldwide. Future plans include all infectious disease potentially affecting domesticated livestock as well wildlife intended for human consumption, particular priority being given to Mad Cow and Foot & Mouth diseases in cattle.
GeneThera's PURIVAX? is a revolutionary system that dramatically improves biological purity and viral titer of recombinant Adenovirus and AAV vectors. PURIVAX? completely eliminates toxic side effects associated with adenoviruses and AAV vectors making it possible to develop highly immunogenic and safe recombinant DNA vaccines.
"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.
Contact:
Contact Information:
The Regency Group
Aaron Lamkin
(303) 771-7300
http://www.regency-financial.com
GeneThera, Inc.
Dr. Tony Milici, CEO
(303) 463-6371
http://www.genethera.net
Source: GeneThera, Inc.
